Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 4:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: NASH Fibrosis Clear all
Recruiting Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

NCT06318169
View directory record Official record
Conditions
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Interventions
Pegozafermin, Placebo
Biological · Other
Lead sponsor
89bio, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
152
States / cities
Birmingham, Alabama • Chandler, Arizona • Flagstaff, Arizona + 131 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 24, 2026, 4:14 AM EDT
Active, not recruiting Not applicable Interventional

Safety and Efficacy of Ketogenic Diet for Promoting Weight Loss in Obese Individuals With Compensated NASH Cirrhosis

NCT04383951
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Liver
Interventions
Dietary consult for participants in the ketogenic diet arm, Dietary consult for participants in the standard of care arm
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Jul 24, 2026, 4:14 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis

NCT04048876
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease, Liver Cirrhosis
Interventions
CC-90001, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
64
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Jul 24, 2026, 4:14 AM EDT
Suspended Phase 3 Interventional Results available

A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR)

NCT04104321
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
Aramchol free acid, Placebo
Drug
Lead sponsor
Galmed Research and Development, Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Miami, Florida • Arlington, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Jul 24, 2026, 4:14 AM EDT
Terminated Phase 1 Interventional Results available

A Study to Evaluate How Ontamalimab Works and Assess Its Safety and Tolerability in People With Nonalcoholic Steatohepatitis With Fibrosis Stages 1 to 4

NCT07052682
View directory record Official record
Conditions
Steatohepatitis
Interventions
Ontamalimab
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 70 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
15
States / cities
Chandler, Arizona • Tucson, Arizona • Coronado, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2025 · Synced Jul 24, 2026, 4:14 AM EDT
Completed Phase 2 Interventional Results available

A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects

NCT04480710
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver, NAFLD - Nonalcoholic Fatty Liver Disease
Interventions
CRV431 75mg, Placebo (1 softgel), CRV431 225mg, Placebo (3 softgels)
Drug
Lead sponsor
Hepion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Orange, California • Poway, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2022 · Synced Jul 24, 2026, 4:14 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

NCT05364931
View directory record Official record
Conditions
Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
Interventions
Cotadutide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
29
States / cities
Tucson, Arizona • Canoga Park, California • Gilroy, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Jul 24, 2026, 4:14 AM EDT
Recruiting Not applicable Interventional

Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial

NCT06138821
View directory record Official record
Conditions
Obesity, Liver Diseases, Liver Fibrosis, Liver Fat, Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis, MASLD, MASH, Weight Loss, Insulin Resistance, Insulin Sensitivity, Insulin Sensitivity/Resistance, Metabolic Disease, Diabetes, Diabetes Mellitus, Type 2, NASH With Fibrosis, Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver, Non-alcoholic Steatohepatitis
Interventions
ESG + lifestyle modification, Lifestyle modification
Device · Behavioral
Lead sponsor
Pichamol Jirapinyo, MD, MPH
Other
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 24, 2026, 4:14 AM EDT
Recruiting No phase listed Observational

Evaluation of Non-Invasive Tests for Metabolic Liver Disease

NCT07122700
View directory record Official record
Conditions
Metabolic Associated Fatty Liver Disease, Metabolic Associated Steatotic Liver Disease, Cirrhosis, Liver, NASH, Liver Fibrosis, Liver Fat, Liver Steatoses, Liver Inflammation
Interventions
Not listed
Lead sponsor
Foundation for the National Institutes of Health
Other
Eligibility
18 Years to 75 Years
Enrollment
400 participants
Timeline
2025 – 2026
U.S. locations
4
States / cities
Miami, Florida • Columbus, Ohio • Bellaire, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Jul 24, 2026, 4:14 AM EDT
Completed Not applicable Interventional

The Availability of the Enhanced Liver Fibrosis (ELF) Test Affects the Rate of Diagnosis of Nonalcoholic Steatohepatitis (NASH) With Fibrosis in Patients Referred to Hepatology

NCT05370053
View directory record Official record
Conditions
Fatty Liver, NAFLD
Interventions
ELF Test
Diagnostic Test
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Jul 24, 2026, 4:14 AM EDT
Completed Not applicable Interventional

Clinical Performance of LIVERFASt Test Compared w/ Liver Biopsy in Patients w/ NAFLD.

NCT04579874
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis, Liver Fibroses, Liver Inflammation, Liver Steatoses
Interventions
LIVERFASt
Diagnostic Test
Lead sponsor
Fibronostics USA, Inc
Other
Eligibility
18 Years to 80 Years
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
8
States / cities
Detroit, Michigan • St Louis, Missouri • Manhasset, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Jul 24, 2026, 4:14 AM EDT
Terminated Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-963272 in Participants With Nonalcoholic Fatty Liver Disease

NCT04766476
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease
Interventions
BMS-963272, Placebo matching BMS-963272
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
19
States / cities
Cullman, Alabama • Chandler, Arizona • Tucson, Arizona + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Jul 24, 2026, 4:14 AM EDT
Withdrawn No phase listed Observational

Natural History of Non Alcoholic Fatty Liver Disease and Predictors of Advanced Fibrosis

NCT05050721
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis (NASH)
Interventions
CT imaging
Other
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Timeline
2019 – 2021
U.S. locations
1
States / cities
Irving, Texas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2021 · Synced Jul 24, 2026, 4:14 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Quantifying Body Composition and Liver Disease in Children Using Free-Breathing MRI and MRE

NCT04591106
View directory record Official record
Conditions
NAFLD, NASH - Nonalcoholic Steatohepatitis
Interventions
Magnetic resonance imaging (MRI), Magnetic resonance elastography (MRE), Prototype MRE soft flexible passive transducer paddle
Diagnostic Test · Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
1 Week to 40 Years
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Jul 24, 2026, 4:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986036 in Participants With Normal Liver Function and Participants With Moderate and Severe Liver Impairment

NCT04634149
View directory record Official record
Conditions
Moderate Liver Impairment, Severe Liver Impairment
Interventions
BMS-986036
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
21 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Jul 24, 2026, 4:14 AM EDT
Terminated Phase 2 Interventional Results available

Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis

NCT03059446
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, Liver Cirrhosis, Non-alcoholic Fatty Liver Disease
Interventions
Cenicriviroc
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
41
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Jul 24, 2026, 4:14 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

NCT03449446
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
SEL, FIR, CILO, Placebo to match FIR, Placebo to match CILO, Placebo to match SEL
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
81
States / cities
Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Jul 24, 2026, 4:14 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of ID119031166M With the Exploration of Pharmacodynamic Effects

NCT05604287
View directory record Official record
Conditions
Healthy Participants
Interventions
ID119031166M, Placebo
Drug
Lead sponsor
IlDong Pharmaceutical Co Ltd
Industry
Eligibility
18 Years to 70 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Jul 24, 2026, 4:14 AM EDT
Completed Phase 1 Interventional

A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients

NCT04483947
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis (NASH)
Interventions
AZD2693, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
16
States / cities
Chula Vista, California • La Mesa, California • Montclair, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Jul 24, 2026, 4:14 AM EDT
Completed Phase 2 Interventional Results available

Treating Nonalcoholic Steatohepatitis (NASH) With Metformin

NCT00063232
View directory record Official record
Conditions
Hepatitis
Interventions
Metformin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 19, 2011 · Synced Jul 24, 2026, 4:14 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of Rencofilstat in Adult Subjects With NASH F3

NCT05461105
View directory record Official record
Conditions
NASH With Fibrosis
Interventions
rencofilstat, 75 mg, rencofilstat, 150mg, rencofilstat, 225 mg
Drug
Lead sponsor
Hepion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
20
States / cities
Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Jul 24, 2026, 4:14 AM EDT
Terminated No phase listed Observational

Genetic Studies of Non-Alcoholic Fatty Liver Disease

NCT01629095
View directory record Official record
Conditions
Non-Alcoholic Steato-Hepatitis, Liver Cirrhosis, Non-Alcoholic Fatty Liver Disease
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
1 Month and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
5
States / cities
San Francisco, California • Bethesda, Maryland • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2020 · Synced Jul 24, 2026, 4:14 AM EDT
Terminated Phase 3 Interventional Results available

Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment

NCT02548351
View directory record Official record
Conditions
Non Alcoholic Steatohepatitis (NASH)
Interventions
Obeticholic Acid, Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
2,477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
175
States / cities
Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 116 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced Jul 24, 2026, 4:14 AM EDT
Completed No phase listed Observational

Effect of Patient Demographics, Comorbidities, and Medications on Severity of NASH Fibrosis

NCT05357352
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis
Interventions
NAFLD/NASH
Other
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Jul 24, 2026, 4:14 AM EDT